Taysha Gene Therapies Inc (NASDAQ: TSHA) kicked off on Friday, down -3.51% from the previous trading day, before settling in for the closing price of $2.85. Over the past 52 weeks, TSHA has traded in a range of $1.05-$4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 94.30%. While this was happening, its average annual earnings per share was recorded 6.82%. With a float of $176.26 million, this company’s outstanding shares have now reached $205.05 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 72.63%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 17.89%, while institutional ownership is 75.84%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.89% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Take a look at Taysha Gene Therapies Inc’s (TSHA) current performance indicators. Last quarter, stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 81.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 4.24 million, which is a jump from its year-to-date volume of 2.55 million. As of the previous 9 days, the stock’s Stochastic %D was 62.38%. Additionally, its Average True Range was 0.25.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 77.63%, which indicates a significant increase from 64.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 117.06% in the past 14 days, which was higher than the 106.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.86, while its 200-day Moving Average is $1.94. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.88. Second resistance stands at $3.00. The third major resistance level sits at $3.16. If the price goes on to break the first support level at $2.59, it is likely to go to the next support level at $2.44. Now, if the price goes above the second support level, the third support stands at $2.31.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
The company with the Market Capitalisation of 590.32 million has total of 214,662K Shares Outstanding. Its annual sales at the moment are 8,330 K in contrast with the sum of -89,300 K annual income. Company’s last quarter sales were recorded 2,300 K and last quarter income was -21,530 K.
